Clinical bottom line
Novel combination therapies in metastatic castration-resistant prostate cancer (mCRPC) show promising efficacy and manageable safety profiles, expanding treatment options beyond traditional androgen deprivation and chemotherapy. Emerging immunotherapy approaches, including bispecific antibodies targeting prostate-specific membrane antigen (PSMA) and immune checkpoint modulation, demonstrate preliminary clinical activity. Additionally, next-generation androgen receptor antagonists like darolutamide continue to improve disease control with favorable tolerability. However, current evidence is largely early-phase and hypothesis-generating, requiring further validation in larger randomized trials (Bansal et al., 2021; Lim et al., 2023).
What the evidence shows
Immunotherapy combinations represent a key area of investigation in mCRPC, a historically immunologically “cold” tumor. Bansal et al. (2021) review multiple strategies combining immune checkpoint inhibitors with other agents to enhance antitumor immunity. While single-agent checkpoint blockade has shown limited efficacy, combination regimens may overcome resistance mechanisms.
Lim et al. (2023) report a phase 1 study of JNJ-63898081, a bispecific antibody engaging PSMA on tumor cells and CD3 on T cells, designed to redirect cytotoxic T cells against prostate cancer. Early clinical activity was observed in heavily pretreated patients, with manageable adverse events primarily consisting of cytokine release syndrome and infusion reactions.
Darolutamide, a novel androgen receptor antagonist with a distinct chemical structure, has demonstrated efficacy in mCRPC with a favorable safety profile and minimal blood-brain barrier penetration, potentially reducing central nervous system side effects (Fizazi et al., 2018). Its role in combination regimens is under active exploration.
Karp et al. (2022) describe PT-112, a pyrophosphate-platinum compound inducing immunogenic cell death, currently in phase 1 trials for advanced solid tumors including prostate cancer. This agent may synergize with immunotherapies by enhancing tumor antigen presentation.
Caveats and uncertainty
Most data derive from early-phase clinical trials with small patient cohorts and short follow-up, limiting definitive conclusions about long-term efficacy and safety. The heterogeneity of mCRPC and prior treatments complicates interpretation.
Immunotherapy-related toxicities, including immune-mediated adverse events and cytokine release syndrome, require careful monitoring and management. Optimal patient selection biomarkers remain under investigation.
Combination regimens increase complexity and cost, and their integration into existing treatment algorithms is not yet standardized. Larger randomized controlled trials are needed to confirm benefits and define sequencing.
How this may change practice
Clinicians should remain informed about emerging combination therapies as potential options for mCRPC patients, particularly those refractory to standard treatments. Participation in clinical trials is encouraged to access novel agents and contribute to evidence generation.
Multidisciplinary collaboration is essential to manage complex toxicities and optimize therapeutic sequencing. Biomarker development may enable personalized treatment approaches.
As evidence matures, combination immunotherapies and next-generation androgen receptor antagonists may become integral components of mCRPC management, potentially improving survival and quality of life.